VANCOUVER, British Columbia, Sept. 21, 2005 (PRIMEZONE) -- After extensive testing by ProtoKinetix, Inc. (OTCBB:PKTX) on a wide range of cells and tissue, the Company has determined that their synthetic AFGP molecule is effective in increasing survival at temperatures above and below freezing. As part of ProtoKinetix' commercialization strategy, Dr. John Todd, president and CEO, announces today that this unique family of synthetic AFGP molecules will now be designated AAGP's to avoid the misconception that their effectiveness is limited to freezing temperatures. This new trademark -- AAGP(tm) -- will more accurately describe the ability of these molecules to dramatically slow the aging process (Age Arresting Glyco Protein) on blood products, organs, skin cells and cell cultures.
As previously announced, ProtoKinetix has entered into several agreements with institutions and corporations for product testing and development. In order to accelerate the commercial exploitation of AAGP(tm), the Company has retained ProteoCell Biotechnologies, Inc. in a broad-based contract that will give PKTX the ability to produce data on multiple commercial applications simultaneously.
ProtoKinetix has made arrangements to increase their current productive capacity by more that one hundred times (100x). This more sophisticated and advanced manufacturing capability will alleviate our current restricted supply that has been overwhelmed by demand from institutions and corporations around the world.
About ProtoKinetix
ProtoKinetix Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast-track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President